BROOKE MATUS: Open Payments
NPI 1144955352 · GENEVA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$440 in 26 payments from 7 companies in 2025. Trend: 2023 $368 · 2024 $320 · 2025 $440
Food & beverage: $440
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $140 |
| Novartis Pharmaceuticals Corporation | 4 | $90 |
| AstraZeneca Pharmaceuticals LP | 4 | $74 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $49 |
| Novo Nordisk Inc | 2 | $34 |
| Boston Scientific Corporation | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
Products named: ELIQUIS, LEQVIO, JARDIANCE, Wegovy, FARXIGA, WATCHMAN, AMVUTTRA, LOKELMA.
Industry payments across NY — which companies pay providers there.
